A phase I study of TLR9 stimulation combined with rituximab in non-Hodgkin lymphoma showed no toxicity, induction of interferon and interferon inducible genes and an overall response rate of 32% (6/19) [65]. The gene discussed is TLR9; the disease is non-Hodgkin lymphoma.